
    
      Approximately 30 subjects will be enrolled in a single-center, open-label study of the
      treatment of psoriasis. There will be a screening/baseline, week 4, week 16 and week 20
      visits. Subjects will include those who have been started on commercial Otezla within the
      last 10 days of baseline. We will add Enstilar foam QD at baseline visit for 4 weeks. Those
      subjects who achieve clear or almost clear on PGA scale at week 4 will continue on
      maintenance dose of Enstilar twice weekly on Mondays and Thursdays QD for the next 12 weeks
      and they will also continue on Otezla. Subjects will continue to week 20 after stopping
      Enstilar at week 16..
    
  